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Abstract 
Objective. To review the available evidence on TNF inhibitor monotherapy versus add-on 
therapy to ongoing methotrexate (MTX) in psoriatic arthritis (PsA). 
Methods. A literature search was conducted up to and including October 2013 for 
randomized controlled trials (RCTs) and observational studies comparing TNF inhibitor 
monotherapy versus combination therapy with MTX in patients with PsA. Key information 
was extracted from the abstracts and/or full text of articles retrieved. 
Results. Eleven published articles and three conference abstracts were retrieved, reporting 
on six RCTs of four TNF inhibitors. Most RCTs found no differences in efficacy for peripheral 
arthritis between patients treated with or without MTX. However, the studies were not 
powered to answer this question. Some data suggest that concomitant MTX may reduce 
progression of structural damage. No significant differences in other outcomes have been 
reported. Data on TNF inhibitor monotherapy versus MTX combination therapy was 
reported from six registries. Three registries reported that use of concomitant MTX did not 
affect the efficacy of TNF inhibitor therapy. Data from three EU registries suggest that TNF 
inhibitor (especially monoclonal antibody) drug survival is superior in patients taking 
concomitant MTX, while one Canadian registry reported no difference.  
Conclusions. Available evidence on the efficacy and safety of TNF inhibitor monotherapy 
versus add-on to MTX shows little or no improvement with combination therapy, although 
use of concomitant MTX appears to prolong TNF inhibitor drug survival of monoclonal 
antibody TNF inhibitors. Registries and observational studies have the potential to fill some 
of the knowledge gaps in this area. 
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Introduction 
Tumour necrosis factor (TNF) inhibitors have been shown to be effective in the treatment of 
both skin and joint symptoms of psoriatic arthritis (PsA) [1], with remission being an 
achievable target [2]. The European League Against Rheumatism (EULAR) and Group for 
Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommend TNF 
inhibitor therapy in PsA patients with an inadequate response to at least one disease-
modifying anti-rheumatic drug (DMARD), or those with predominantly axial disease, 
dactylitis or enthesitis. Methotrexate (MTX) is the suggested first-line DMARD in PsA; 
however, neither EULAR nor GRAPPA currently recommend the use of MTX in combination 
with TNF inhibitor therapy owing to the availability of insufficient data [3, 4]. 
Despite this, the use of MTX in combination with TNF inhibitors in PsA is not uncommon; 
there could be several reasons for this. Firstly, rheumatologists are accustomed to using 
concomitant MTX with TNF inhibitor therapy in rheumatoid arthritis (RA). Combination 
therapy with MTX has demonstrated superior efficacy compared with biologic monotherapy 
for the treatment of RA and this approach is recommended by EULAR [5]. MTX is also an 
effective therapy in psoriasis, but combination use with TNF inhibitors has been less well 
studied than in RA [6]. In two small clinical trials, the combination of etanercept and MTX 
showed greater efficacy than monotherapy for skin outcomes in psoriasis patients [6, 7]. 
There is also some evidence from a small observational study that the addition of MTX may 
improve treatment efficacy in psoriasis patients with an inadequate response to 
adalimumab [8]. Conversely, a small observational study did not find any difference in 
efficacy between infliximab monotherapy and combination therapy with MTX in psoriasis 
patients [9]. Concomitant MTX may reduce the risk of infusion reactions in psoriasis patients 
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treated with infliximab [10]. The addition of MTX to infliximab reversed the anti-drug 
antibody (ADA) status and achieved sustained clinical efficacy in ADA-positive psoriasis 
patients in a small pilot study [11]. 
The potential effect of MTX on the formation of ADAs, especially in the case of monoclonal 
antibody (mAb) TNF inhibitors, could also support the concomitant use of MTX in PsA. The 
development of ADAs against mAb TNF inhibitors in PsA patients is associated with low 
serum drug levels and diminished clinical response [12]. Concomitant MTX has been shown 
to reduce immunogenicity in a dose-dependent manner in adalimumab-treated RA patients 
[13]. MTX also reduced immunogenicity of infliximab in a study of 94 patients with 
spondyloarthritis (including 22 patients with PsA) [14]. Recently, the use of concomitant 
MTX was shown to reduce immunogenicity of adalimumab and infliximab in an Israeli cohort 
of 93 PsA patients [15].  
In this review, we address the role of concomitant MTX in PsA patients (excluding those with 
psoriasis only) by examining the available evidence for TNF inhibitor combination therapy 
with MTX, especially with regards to TNF inhibitor monotherapy, and help to identify 
knowledge gaps around this topic.  
 
Methods 
A search of PubMed was conducted up to and including October 2013 for randomized 
controlled trials (RCTs) and observational studies comparing TNF inhibitor monotherapy 
versus add-on therapy to ongoing MTX in patients with PsA. The search terms used were: 
“Psoriatic arthritis” AND (“TNF” OR “adalimumab” OR “certolizumab” OR “etanercept” OR 
“golimumab” OR “infliximab”) . Relevance to the topic was determined by scanning the title 
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and abstract of the retrieved articles. Full text articles were obtained if the abstract did not 
contain sufficient information to determine relevance. Articles were included in the review 
only if they reported data for PsA patients treated with a TNF inhibitor alone versus those 
receiving a TNF inhibitor in combination with MTX. In addition, titles of abstracts from 
appropriate sessions of EULAR Congresses in 2011–13 and American College of 
Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHC) Annual 
Meetings in 2011–13 were scanned for relevant new data not fully published at the time of 
the search. 
Information extracted from reports of RCTs included inclusion criteria, baseline disease and 
treatment data, MTX dose, efficacy outcomes for joint and skin symptoms, safety outcomes 
and ADA formation. Information extracted from observational studies included PsA severity 
and duration, concomitant treatment, and efficacy, safety and drug survival data. 
 
Results 
Figure 1 illustrated the process of publication selection. The searches using the names of 
individual TNF inhibitors returned 1610 articles (372 for adalimumab, 23 for certolizumab, 
601 for etanercept, 65 for golimumab and 549 for infliximab). After assessment of relevance 
and exclusion of duplicates, 36 potential articles remained for inclusion. The search 
replacing individual drug names with “TNF” returned one additional relevant article. 
Searches of conference abstracts found four relevant abstracts. 
 
Randomized controlled trials 
8 
 
Eleven published articles and three conference abstracts were retrieved, reporting on six 
RCTs of four TNF inhibitors. Two articles reported on the ADEPT trial of adalimumab [16, 
17]. Two articles reported on two RCTs of etanercept [18, 19], and a conference abstract 
reported a post-hoc analysis of pooled data from these trials [20]. Two articles and two 
conference abstracts reported on the GO-REVEAL trial of golimumab [21-24]. Five articles 
reported on two trials (IMPACT and IMPACT 2) of infliximab [25-29]. 
In addition, one article reported on the RAPID-PsA trial of certolizumab pegol, but only data 
for monotherapy versus any concomitant DMARD therapy (not specifically MTX) were 
available [30]. 
Some key inclusion criteria and baseline characteristics of the included RCTs are shown in 
Table 1. 
 
Efficacy data in RCTs 
ACR response rates 
All RCTs found no or minor differences in efficacy for peripheral arthritis, as assessed by ACR 
response rates, between patients treated with or without MTX (Table 2). No statistical 
analyses comparing monotherapy and combination therapy were performed in any of the 
trials; comparisons were based solely on numerical values. 
The ADEPT adalimumab trial found no differences for ACR20, ACR50 or ACR70 at weeks 12 
and 48 [16, 17]. Similarly, the GO-REVEAL golimumab trial reported no effect of concomitant 
MTX on ACR20, 50 or 70 at 14 weeks [21], 2 years [22] or 5 years [23, 24]. 
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No differences in response to etanercept with or without MTX at week 12 were reported by 
Mease et al. or for the PRESTA trial [18, 19]. A post-hoc analysis of pooled data from Mease 
et al. and PRESTA found no differences between etanercept (n=322) and etanercept plus 
MTX (n=153) arms in ACR20 at 24 weeks (71% vs. 70%); numerically, a higher proportion of 
patients in the monotherapy arm achieved ACR50 (55% vs. 48%) and ACR70 (35% vs. 27%) 
responses [20]. 
In the IMPACT trial of infliximab, concomitant use of MTX had no effect on ACR20 response 
at week 16 [25]. In IMPACT 2, numerically fewer MTX users achieved an ACR50 and ACR70 
response at week 14 than MTX non-users (see Table 2), although the number of patients 
included in these analyses was small [26]. There was no difference between the two groups 
in ACR20 response at week 14 or in any ACR response at week 24 [26]. The ACR response at 
week 54 was consistent, regardless of baseline MTX use [28]. 
In addition, the RAPID-PsA trial of certolizumab pegol found no difference in ACR20 at 12 
weeks between groups with and without concomitant DMARDs for either certolizumab dose 
investigated [30]. 
 
Structural outcomes 
Three RCTs reported structural outcomes in patients with and without MTX (Table 2). ADEPT 
found no effect of MTX on radiographic progression in adalimumab-treated patients at 
week 24, although there was some suggestion of a difference at week 48 (mean mTSS 
change -0.1 with MTX vs. 0.4 without MTX) [17]. In GO-REVEAL, patients receiving MTX at 
baseline demonstrated numerically less progression at week 104 than patients not receiving 
MTX despite having more radiographic damage at baseline (mean change from baseline in 
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modified Sharp/van der Heijde score [SHS] -0.78 vs. 0.03 for golimumab 50 mg every 4 
weeks and -0.65 vs. 0.00 for 100 mg) [22]. A similar pattern was seen at week 256 [23, 24]. 
In IMPACT 2, the difference in radiographic progression at 1 year between infliximab and 
placebo groups was greater in patients with baseline MTX use (median difference between 
treatment groups in change from baseline in total modified SHS 0.5 vs. 0.0) [29]. 
 
Other arthritis outcomes 
In IMPACT 2, significant improvements in Health Assessment Questionnaire Disability Index 
(HAQ-DI) scores were seen in the infliximab group compared with the placebo group, 
regardless of MTX use at baseline [27]. Mean percentage improvement from baseline in 
HAQ at week 14 was 34% in patients receiving infliximab and MTX (versus 3.7% for placebo) 
and 61% (versus -36% [i.e. worsening] for placebo) in those receiving infliximab 
monotherapy. A similar pattern was seen at week 24 [27].  
The pooled analysis of etanercept trials found little numerical difference between 
etanercept alone and etanercept plus MTX arms for DAS28 (change from baseline -1.9 vs. -
1.8), Psoriatic Arthritis Response Criteria (PsARC) response (80% vs. 83%) or HAQ-DI (change 
from baseline -0.5 vs. -0.6) at week 24 [20]. 
 
Skin outcomes in PsA patients 
In ADEPT, Psoriasis Area Severity Index (PASI) 50, 75, 90 and 100 response rates were 
numerically greater in the adalimumab plus MTX sub-group at week 48 (83% vs. 55%, 72% 
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vs. 48%, 59% vs. 38% and 41% vs. 28%, respectively), but the difference was only significant 
for PASI 50 (p<0.05) [17]. 
PRESTA found some benefit of MTX for skin symptoms at week 12 in patients with severe 
skin disease (mean baseline PASI of 20) receiving etanercept 50 mg twice weekly but not 
those receiving 50 mg once weekly [19]. The pooled analysis of etanercept trials found little 
numerical difference in PASI improvement from baseline to week 24 between etanercept 
only and etanercept plus MTX arms (change from baseline -14 vs. -12) [20]. 
In GO-REVEAL, in the 217/292 (74%) patients with at least 3% body surface area affected, 
benefit of golimumab on PASI at week 14 was observed irrespective of MTX use (P=0.32) 
[21]. At week 104, similar PASI 50, 75 and 90 responses were seen irrespective of baseline 
MTX use (monotherapy 81% vs. MTX 88%, 64% vs. 62% and 44% vs. 38%, respectively, for 
golimumab 50 mg; 83% vs. 89%, 73% vs. 71% and 51% vs. 42%, respectively, for 100 mg) 
[22]. At week 256, PASI responses were similar in patients treated with and without MTX 
[23, 24]. 
In IMPACT 2, compared with patients not receiving MTX at baseline, those receiving MTX in 
combination with infliximab had similar PASI 75 responses at week 54 (48% vs. 53%, 
respectively) [28]. 
 
QoL outcomes 
In IMPACT 2, significant benefits, as measured by SF-36 scores, were seen in the infliximab 
group compared with placebo, regardless of baseline MTX use [27]. For MTX users, the 
mean improvement from baseline at week 14 was 7.9 in the infliximab group versus 2.9 in 
the placebo group for the physical component summary (PCS) score and 2.0 versus -3.4 
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(worsening) for the mental component summary (MCS) score. For non-MTX users, the 
corresponding improvement was 10.1 in the infliximab group versus -0.5 (worsening) in the 
placebo group for the PCS score, and 5.3 versus 0.6 for the MCS score. A similar pattern was 
found when the data were analysed at week 24 [27]. 
 
Safety data in RCTs 
In ADEPT, nine patients had serum transaminase values three times the upper limit of 
normal; five of these patients were receiving MTX [17]. In GO-REVEAL, concomitant MTX did 
not appear to affect transaminase levels at week 14 [21]. 
In IMPACT 2, five patients on infliximab had markedly abnormal alanine transaminase (ALT) 
or aspartate transaminase (AST) levels at week 24; one of these patients was on MTX [26]. 
At week 54, the incidence of adverse events was generally similar between patients 
receiving MTX and those not receiving MTX at baseline (88% vs. 83%) [28]. Slightly more 
infliximab-treated patients not receiving MTX had an ALT or AST value that rose from 
normal to high compared with those receiving MTX (47% vs. 40% and 31% vs. 22%, 
respectively). The rate of infusion reactions was lower in patients receiving MTX at baseline 
(0.9% vs. 3.2%) [28]. 
 
Immunogenicity data in RCTs 
In GO-REVEAL, the incidence of antibodies to golimumab at week 14 was low (4.6%), and no 
patients receiving MTX at baseline developed antibodies [21]. By week 104, 5.4% of 
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golimumab-treated patients had developed antibodies; this appeared to be less common in 
patients receiving (1.6%) than those not receiving MTX at baseline (9.1%) [22].  
In IMPACT 2, only 3.6% of patients receiving MTX at baseline were positive for antibodies to 
infliximab through week 66 compared with 26.1% of those not receiving MTX [28]. ACR 
improvement at week 54 was lower (22% vs. 33%) and mild-to-moderate infusion reactions 
were 3.5-fold more common in patients with ADAs [28]. 
 
Observational studies/registries 
Seven published articles and one conference abstract reported TNF inhibitor monotherapy 
versus MTX combination therapy data from six registries [31-38]. Characteristics of the 
registries and PsA patients included are shown in Table 3. In addition, one article and one 
abstract reported data on TNF inhibitor therapy with and without concomitant DMARDs 
(not specifically MTX) [39, 40]. Three reports of relevant observational studies were also 
retrieved [41-43]. 
In three registries (BSRBR, NOR-DMARD, ROB-FIN) that reported efficacy data, use of 
concomitant MTX did not affect the efficacy of TNF inhibitor therapy [34, 35, 38].  
 
Registries – drug survival data 
Drug survival data were reported for four registries. In the Norwegian DMARD registry 
(NOR-DMARD), concomitant MTX was associated with better 1-year TNF inhibitor drug 
survival in PsA patients (p=0.02) [31]. Reasons for discontinuing treatment were: lack of 
efficacy (18%), adverse events (69%), patient request (5%) and other reason/unknown (8%). 
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Discontinuation rates in the monotherapy versus combination therapy groups were not 
reported; however, no combination treatment courses were discontinued due to lack of 
efficacy, whereas lack of efficacy was the reason for about 40% of monotherapy 
discontinuations [31]. 
In another analysis of NOR-DMARD data, the difference in TNF inhibitor drug survival with 
concomitant MTX was most prominent for patients receiving infliximab [32]. The groups of 
patients receiving TNF inhibitor as monotherapy (n=170) and those receiving concomitant 
MTX (n=270) had similar baseline characteristics, except for a higher swollen joint count in 
the concomitant MTX group. Drug survival analyses showed a borderline significant 
difference in favour of patients receiving MTX (p=0.07); this was most prominent for 
patients receiving infliximab (p=0.01). A similar trend was seen for patients treated with 
adalimumab (p=0.12); the group difference in the etanercept group was negligible (p=0.79). 
In a Cox regression analysis, lack of concomitant MTX and current smoking were 
independent predictors of TNF inhibitor discontinuation. Reasons for discontinuation were 
loss/lack of efficacy (monotherapy 20% versus concomitant MTX 14%), adverse events (21% 
vs. 14%) and other (13% vs. 18%). Patients receiving infliximab as monotherapy had 
markedly higher discontinuation rates due to adverse events (p<0.001) [32]. 
The South Swedish Arthritis Treatment Group (SSATG) noted no baseline differences 
between 100 patients receiving TNF inhibitor monotherapy and 161 receiving concomitant 
MTX, other than greater NSAID use in the MTX group (61% [98/161] vs. 48% [48/100]; 
p=0.04) [33]. Concomitant MTX (hazard ratio 0.64, 95% CI 0.39–0.95; p=0.03), use of 
etanercept (0.49, 0.28–0.86; p=0.01) and high C-reactive protein levels (0.77, 0.61–0.97; 
p=0.03) at treatment initiation were associated with better overall drug survival over 7 
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years. The improved drug survival with concomitant MTX appeared to be related to 
significantly fewer dropouts because of adverse events (hazard ratio 0.24, 0.11–0.52; 
p<0.01) [33]. 
In the Danish biologics registry (DANBIO), 54% of 410 PsA patients were receiving 
concomitant MTX at baseline [36]. Baseline MTX use was more prevalent among patients 
receiving infliximab (70%) than adalimumab (49%) or etanercept (39%) (p<0.001). After 3 
months, 329 (80%) patients continued to receive concomitant MTX, 44 patients (11%) had 
stopped MTX but continued TNF inhibitor therapy, and 37 patients (9%) had stopped 
receiving a TNF inhibitor. In a Cox regression analysis, male gender, CRP level >10 mg/L, 
concomitant MTX use, and low patient health visual analogue scale score at baseline were 
associated with longer drug survival. The adjusted hazard ratio for discontinuation of TNF 
inhibitor associated with lack of MTX use was 1.37 (95% CI 1.07–1.75). Lack of MTX use was 
associated with discontinuation due to adverse events but not due to lack of efficacy [36]. 
In contrast to the above findings, the Canadian Rhumadata clinical database and registry 
found that concomitant  MTX did not demonstrate improved 5-year retention with 
adalimumab or etanercept (52% for combination therapy versus 67% for monotherapy; 
p=0.74) [37]. 
In addition, there were two reports of TNF inhibitor drug survival with and without 
concomitant DMARDs (not specifically MTX). The British Society of Rheumatology Biologics 
Register (BSRBR) reported that, for TNF inhibitor discontinuation due to inefficacy, there 
was a trend towards better survival in patients receiving concomitant DMARD therapy [39]. 
The particular DMARDs used were not specified. Finally, in the US CORRONA registry, 
patients initiated on biologic–DMARD combination therapy had slightly higher disease 
16 
 
severity at baseline and were at higher risk of changing therapy compared with those 
receiving biologic monotherapy [40]. 
 
Other observational studies 
A non-interventional study of 95 PsA patients treated with TNF inhibitors found that 
concomitant MTX did not predict response (defined as an improvement of 40% in active 
and swollen joint count and 50% improvement in PASI score) in the logistic regression 
models used [41]. An Italian multicenter longitudinal pilot study found no difference in 
efficacy between TNF inhibitors with or without concomitant MTX in PsA patients, but the 
number of patients was very small (n=29) [42]. 
Finally, a prospective observational study of 82 PsA patients treated with etanercept with or 
without concomitant MTX in one Italian center found that the main demographic and 
clinical features, including rates of withdrawal due to inefficacy or toxicity, were not 
significantly different in patients with PsA treated with etanercept alone or in combination 
with MTX; concomitant MTX treatment did not appear to be a positive predictor of drug 
survival [43].  
 
Discussion 
Among six RCTs of TNF inhibitors in PsA, most found no effect of concomitant MTX on 
efficacy outcomes, and one study of infliximab (IMPACT 2) actually found numerically lower 
ACR50 and ACR70 responses at week 14 in patients taking concomitant MTX [26]. It should 
be noted that these studies were not sufficiently powered to answer this question and no 
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statistically tests were conducted. Some data suggest that concomitant MTX may reduce 
structural progression, with numerically less progression at weeks 104 and 256 in patient 
receiving MTX and golimumab in GO-REVEAL [22-24] and a greater difference in 
radiographic progression at 1 year between infliximab and placebo groups with concomitant 
MTX in IMPACT 2 [29]. No significant differences in other outcomes have been reported, 
other than some benefit of MTX for skin symptoms at week 12 in patients with severe skin 
symptoms receiving etanercept 50 mg twice weekly (but not 50 mg once weekly) in PRESTA 
[19]. No randomized trials designed to compare TNF inhibitor monotherapy versus 
concomitant MTX have been performed to date; the comparisons reported are based on 
stratification rather than randomization, and baseline differences need to be taken into 
account. 
It has been suggested that the lack of improvement in efficacy with MTX and TNF inhibitor 
combination therapy may be due to differences in the efficacy of MTX in PsA versus RA [16]. 
A study of MTX in PsA found no evidence for improvement of synovitis [44]. Alternatively, 
the efficacy of TNF inhibitors at the studied doses in PsA RCTs is already maximal and 
therefore not subject to improvement via the mechanisms that MTX might have in RA (e.g. 
an additive immunomodulatory effect or a direct effect on TNF inhibitor clearance 
mechanisms) [16].  
There is little data from RCTs comparing the safety of TNF inhibitors with and without 
concomitant MTX. However, in the IMPACT 2 trial, infusion reactions with infliximab were 
slightly less frequent in patients receiving MTX [28]. In this trial, the low number of patients 
on concomitant MTX who had increased transaminase levels may be due in part to the 3 
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months of MTX exposure at baseline, and hence there may have been some selection bias 
towards patients who were less prone to development of abnormal liver enzymes [28]. 
Formation of ADAs against infliximab and golimumab also appears to be lower in patients 
receiving concomitant MTX [21, 22, 28]. A small study recently demonstrated a significant 
correlation between the use of MTX and the absence of ADAs in PsA patients treated with 
infliximab and adalimumab [15], but more data is needed before the use of MTX can be 
recommended to reduce immunogenicity in PsA patients. 
Data from three EU registries (BSRBR, ROB-FIN, NOR-DMARD) showed no difference in the 
efficacy of TNF inhibitors with and without concomitant MTX [34, 35, 38]. However, data 
from three EU registries (NOR-DMARD, SSATG, DANBIO) suggest that TNF inhibitor drug 
survival is better in patients taking concomitant MTX [31-33, 36]. Only one of these 
registries separated the data by TNF inhibitor agent [32]. There was no difference in drug 
survival for etanercept with or without MTX, whereas patients receiving infliximab as 
monotherapy had markedly higher discontinuation rates due to adverse events (p<0.001). 
The authors suggested that the difference in drug survival could be explained by 
mechanisms related to the potential for MTX to prevent ADA formation [32]. The other two 
registries reported that lack of MTX appeared to be associated with discontinuation due to 
adverse events rather than lack of efficacy [33, 36]. A Canadian registry found no difference 
in drug survival with or without MTX [37]. 
Confounding by indication is a concern in observational studies. A higher degree of drug 
intolerance and treatment resistance may be present in patients on TNF inhibitor 
monotherapy. Absence of concomitant MTX might be associated with the presence of a co-
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morbidity relevant to drug continuation. MTX use seems to be higher in patients on 
infliximab compared with other TNF inhibitors. 
Overall, there is little evidence to guide physicians treating patients with PsA as to whether 
TNF inhibitors should be used as monotherapy or in combination with MTX. A recent study 
of treatment patterns with adalimumab and etanercept in patients with psoriasis or PsA in 
the setting of a US claims database found that 46.3% of adalimumab-treated and 36.8% of 
etanercept-treated PsA patients were also receiving MTX, compared with 14.4% and 10.4%, 
respectively, of psoriasis patients [45]. 
One possible treatment strategy in PsA might be to add a TNF inhibitor in patients with an 
inadequate response to MTX. Following a good response, MTX could be tapered and then 
possibly withdrawn, although drug survival data suggest this may not be advisable with mAb 
agents. An alternative strategy could be to initiate TNF inhibitor monotherapy and add MTX 
if a partial response is seen. Although RCTs could be designed to answer this question, large 
numbers of patients would be required to identify the most appropriate strategy in a 
controlled environment. Observational studies and analyses of registry data may offer a 
more practical approach. 
 
Conclusions 
Available evidence on the efficacy and safety of TNF inhibitor monotherapy versus 
concomitant MTX shows little or no improvement with combination therapy, although use 
of MTX appears to prolong TNF inhibitor drug survival, especially with mAb TNF inhibitors. 
Information on the use of different treatment strategies in PsA, such as starting with 
combination therapy and then withdrawing MTX or starting with TNF inhibitor monotherapy 
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and then adding MTX, is lacking. Registries and observational studies have the potential to 
address such questions and fill some of the knowledge gaps in this area. 
 
Key messages 
 Combination with MTX does not improve the efficacy or safety of TNF inhibitors in 
PsA 
 Use of concomitant MTX appears to prolong TNF inhibitor drug survival, especially 
with mAbs 
 Information on the use of different treatment strategies in PsA is lacking 
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Figure 1. Flow chart of publication selection 
 
 
 
Citations retrieved through literature search  
(n = 1610) 
1574 citations excluded 
• Not relevant to the review 
Potentially relevant articles  
assessed for eligibility 
(n=37) 
16 articles excluded 
• Ineligible  study designs,  
outcomes or patients  
Studies included (n = 21) 
Randomised controlled trials (n = 11) 
Registry/observational studies (n =10) 
29 
 
Table 1. Characteristics of patients in TNF inhibitor arms of RCTs 
Drug / trial Patient 
population 
TNFi dose / 
duration 
PsA 
duration 
(years) 
PsA type Skin 
involvement 
Disease severity Concomitant 
treatment 
MTX at 
baseline 
Stratified by 
MTX use? 
Joints Skin 
Adalimumab           
ADEPT [16] Mod–severe 
PsA; NSAID-
IR 
40 mg EOW 
for 24 weeks 
(n=151) + OLE 
Mean 9.8 ± 
8.3 
64% symmetric 
polyarthritis 
25% asymmetric 
polyarthritis 
15% DIA 
1% arthritis 
mutilans 
1% spondylitis 
46% 3% 
BSA  
TJC (0–78): 23.9 ± 
17.3 
SJC (0-76): 14.3 ± 
12.2 
HAQ-DI: 1.0 ± 0.6 
Mean PASI: 
7.4 ± 6.0 
NSAIDs, 
prednisolone 
allowed 
51% Yes 
Etanercept           
Mease et al 
[18] 
Active PsA; 
NSAID-IR 
25 mg BIW for 
24 weeks 
(n=101) + OLE 
Mean 9.0 86% polyarthritis 
51% DIA 
41% asymmetric 
peripheral arthritis 
1% arthritis 
mutilans 
3% AS-like arthritis 
Mean BSA: 
10.9% 
  CS 19% 
NSAIDs 88% 
42% (n=42; 
mean dose 16.3 
mg/wk) 
Yes 
PRESTA [19] Mod–severe 
psoriasis 
and PsA 
50 mg 
BIW/QW 
(n=379); 
12/12 weeks 
Mean 7 ± 7   TJC: 19 ± 18 
SJC: 12 ± 15 
Mean BSA: 
31% 
PASI: 20 ± 11 
Stable CS, 
NSAIDs 
allowed 
25% (mean 
dose 12.7 
mg/wk) 
No 
50 mg 
QW/QW 
(n=373); 
12/12 weeks 
Mean 7 ± 7   TJC: 19 ± 18 
SJC: 13 ± 15  
Mean BSA: 
30% 
PASI: 19 ± 10 
Golimumab           
GO-REVEAL 
[21] 
Active PsA 
despite 
NSAIDs 
50 mg Q4W 
(n=146) for 20 
weeks + OLE 
Mean 7.2 ± 
6.8 
16% DIA 
30% asymmetric 
peripheral arthritis 
43% polyarthritis 
1% arthritis 
mutilans 
10% spondylitis + 
peripheral arthritis 
75% 3% 
BSA 
 
TJC: (0–68) 24.0 ± 
17.1 
SJC: (0–66) 14.1 ± 
11.4 
DAS28-CRP: 4.4 ± 
1.1 
Mean PASI: 
9.8 ± 8.6 
Mean BSA: 
16.2% 
CS 13% 
NSAIDs 75% 
49% (n=71; 
mean dose 14.8 
mg/wk) 
Yes 
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100 mg Q4W 
(n=146) for 20 
weeks + OLE 
Mean 7.7 ± 
7.8 
15% DIA 
34% asymmetric 
peripheral arthritis 
38% polyarthritis 
1% arthritis 
mutilans 
12% spondylitis + 
peripheral arthritis 
74% 3% 
BSA 
 
TJC (0–68): 22.5 ± 
15.7 
SJC (0–66): 12.0 ± 
8.4 
DAS28-CRP: 4.3 ± 
1.0 
Mean PASI: 
11.1 ± 9.5 
Mean BSA: 
17.7% 
CS 18% 
NSAIDs 75% 
47% (n=67; 
mean dose 15.5 
mg/wk) 
Infliximab           
IMPACT [25] Active PsA 
6 months; 
failed 1 
DMARD 
5 mg/kg for 16 
weeks (n=52) 
+ OLE  
Mean 11.7 
± 9.8 
100% peripheral 
polyarticular 
arthritis 
42% PASI 
2.5 
TJC (0–68): 23.7 ± 
13.7 
SJC (0–66): 14.6 ± 
7.5 
DAS28: 5.5 ± 1.1 
Mean PASI: 
5.1 ± 5.9 
Stable CS 
and NSAIDs 
allowed 
DMARD 63% 
MTX 46% 
(n=24; mean 
dose 15.9 
mg/wk) 
No 
IMPACT 2 
[26] 
Active PsA 
6 months; 
failed 1 
DMARD or 
NSAID 
5 mg/kg for 24 
weeks (n=100) 
+ OLE  
Mean 8.4 ± 
7.2 
26% DIA 
18% asymmetric 
peripheral arthritis 
53% polyarthritis 
1% arthritis 
mutilans 
2% spondylitis + 
peripheral arthritis 
83% 3% 
BSA 
 
TJC (0–68): 24.6 ± 
14.1 
SJC (0–66): 13.9 ± 
7.9 
HAQ-DI: 1.1 ± 0.6 
Mean PASI: 
11.4 ± 12.7 
CS 15% 
NSAIDs 71% 
47% (n=47; 
mean dose 16 
mg/wk) 
Yes 
AS: ankylosing spondylitis; DIA: distal interphalangeal arthropathy; BIW: twice weekly; BSA: body surface area; CRP: C-reactive protein; CS: corticosteroid; DAS: disease activity score; DMARD: 
disease-modifying anti-rheumatic drug; EOW: every other week; HAQ-DI: Health Assessment Questionnaire Disability Index; IR: inadequate response; MTX: methotrexate; NSAID: non-steroidal 
anti-inflammatory drug; OLE: open-label extension; PASI: Psoriasis Area Severity Index; PsA: psoriatic arthritis; Q4W: every 4 weeks; QW: once weekly; SJC: swollen joint count; TJC: tender joint 
count 
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Table 2. ACR response rates and radiographic changes in RCTs 
Drug / trial Time point / TNFi dose No of patients Mean MTX 
dose 
ACR20 ACR50 ACR70 Mean (± SD) change from 
baseline in mTSS 
Mono + MTX Mono + MTX Mono + MTX Mono + MTX Mono + MTX 
Adalimumab           
ADEPT [16, 17] Week 12 76 75  61%* 55%* 36% 36% 23% 17%  
 Week 24          -0.2 ± 1.17 -0.2 ± 1.59 
 Week 48 66 72  50% 63% 38% 49% 29% 31% 0.4 -0.1 
Etanercept      
Mease et al [18] Week 12* 288 143 16.3 mg/wk 
71% 70% 55% 48% 35% 27% 
 
PRESTA [19] Week 12* 12.7 mg/wk  
Golimumab      
GO-REVEAL [21-
24] 
Week 14* 292  Benefit seen irrespective of MTX use (P=0.66)  
Week 104 50 mg & 
50/100 
mg 
55 63 14.8 mg/wk 64% 70% 44% 49% 24% 34% 0.03 ± 2.25 -0.78 ± 2.04 
100 mg 61 68 15.5 mg/wk 72% 68% 52% 51% 37% 51% 0.00 ± 1.51 -0.65 ± 2.15 
Week 256 204  ACR responses were similar in patients treated with 
and without MTX 
Changes were minimal 
and numerically less in 
patients on MTX 
Infliximab           
IMPACT [25] Week 16* 52 15.9 mg/wk 74% 63% – – – –  
IMPACT 2 [26, 28] Week 14* 
53 47 
16 mg/wk 57% 60% 43% 28% 21% 9%  
Week 24  51% 57% 40% 43% 32% 21% 0.0** 
(p=0.108) 
0.5** 
(p<0.001) 
Week 54 90  61% 57% – – – –  
*Primary endpoint 
**Median difference between treatment groups 
Note: Differences between monotherapy and combination therapy were not tested for statistical significance 
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Table 3. Characteristics of registries 
Registry Region Indication No of TNFi-treated PsA 
patients 
PsA disease duration 
(years) 
Disease severity (joints) Concomitant MTX 
No; % Dose 
NOR-
DMARD [31] 
Norway RA, PsA, AS 172 (48 IFX, 96 ETA, 28 
ADA)  
Mean 12.1 ± 9.3 Global VAS: 43.9 ± 19.3 68%  
NOR-
DMARD [32] 
440 Median 5.2 (IQR 1.5–
12.5) 
SJC (0–32): 3 (IQR 1–6) 
Physician global: 37.4 ± 17.9 
Patient global: 54.6 ± 23.7 
MHAQ 0.70 ± 0.46 
270; 61% Mean 14.7 ± 5.1 
mg/wk 
NOR-
DMARD [38] 
146 (44 IFX, 83 ETA, 19 
ADA) 
Mean 11.6 ± 9.3 SJC (0–28) 4.9 ± 4.8 
TJC (0–28) 7.5 ± 7.0 
Physician global 44.8 ± 19.6 
Patient global 58.1 ± 21.3 
DAS-28 4.8 ± 1.4 
MHAQ 1.83 ± 0.47 
75% IFX, 60% 
ETA, 79% ADA 
Mean 12.5 ± 4.7 
mg/wk 
SSTAG [33] South 
Sweden 
IA 261 (MTX: 17 ADA, 70 
ETA, 74 IFX; no MTX: 11, 
49, 40) 
Median 7.9 (IQR 3.7–
15.0) MTX; 9.4 (4.2–
17.8) no MTX 
HAQ: 1.0 ( IQR 0.6–1.4) MTX; 
1.0 (0.5–1.5) no MTX 
DAS28: 4.9 (3.9–5.7) MTX; 4.8 
(3.8–5.5) no MTX 
161; 62% Median 15.0 (IQR 
10–20) mg/wk 
ROB-FIN 
[35] 
Finland IA 127 (IFX, ETA) Median 11 (IQR 6–
18) 
SJC (0–54): 6 (IQR 3–11) 
TJC (0–53): 7 (4–13) 
HAQ: 1.0 (0.63–1.5) 
Patient global: 59 (42–75) 
Physician global: 50 (45–75) 
51% (IFX 71%; 
ETA 44%) 
Median 13.75 (IQR 
5–25) mg/wk IFX; 
15 (8.75–25) ETA 
DANBIO 
[36] 
Denmark IA 764 (320 ADA, 260 IFX, 
184 ETA) 
Median 5 (IQR 2–11) SJC: 3 (IQR 1–7) 
TJC: 7 (3–13) 
HAQ: 1.0 (0.6–-1.5) 
DAS28: 4.8 (3.9–5.5) 
VAS global: 69 (50–81) 
410; 54% (IFX 
70%, ADA 49%, 
ETA 39%) 
Not reported 
BSRBR [34] UK Primarily 
RA 
596 (333 ETA, 171 IFX, 92 
ADA) 
Mean 12.4 ± 8.7 TJC (0–28) 13.4 ± 7.7 
SJC (0–28) 8.9 ± 6.1 
DAS28 6.4 ± 5.6 
HAQ 1.9 (1.4–2.3) 
Not reported Not reported 
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ADA: adalimumab; AS: ankylosing spondylitis; DAS: disease activity score; DMARD: disease-modifying anti-rheumatic drug; ETA: etanercept; HAQ: Health Assessment 
Questionnaire; IA: inflammatory arthritis; IFX: infliximab; IQR: interquartile range; MTX: methotrexate; PsA: psoriatic arthritis; SJC: swollen joint count; RA: rheumatoid 
arthritis; TJC: tender joint count; TNFi: tumour necrosis factor inhibitor; VAS: visual analogue scale 
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